New study checks how well a targeted breast cancer drug works in russian patients
NCT ID NCT07281001
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will look at medical records of 60 Russian patients with advanced HER2-positive breast cancer who have received trastuzumab deruxtecan. Researchers want to see how long the drug keeps cancer from growing and how safe it is. The goal is to understand how well this treatment works in real-world settings in Russia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan
What this could lead to
If successful, this could confirm that trastuzumab deruxtecan is effective for Russian patients with advanced HER2+ breast cancer, supporting its use in this population.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also small (60 people) and only looks back at existing data, which can have missing information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
RECRUITINGMoscow, 115522, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••